A5074163256- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Neurological Disorders and Treatments
- Blood Pressure and Hypertension Studies
- Stroke Rehabilitation and Recovery
- Atrial Fibrillation Management and Outcomes
Sergiyev Posad Humanitarian Institute
2021-2022
Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky
2018
Evaluation of the safety and effectiveness thrombolytic therapy (TLT) with drug Revelisa (alteplase) in patients ischemic stroke (AI) real clinical practice.An open prospective multicenter non-interventional register study was conducted, which included 550 AI - 259 (47.1%) women 291 (52.9%) men; average age 67.7±12.6 years. All underwent TLT within 4.5 hours from onset disease and, according to protocol reperfusion AI, clinical, instrumental laboratory examinations were performed....
To assess the safety and efficacy of Revelisa in patients with ischemic stroke real-world clinical practice.The interim analysis an open-label, prospective, multicenter, non-interventional study IVT-AIS-R included 223 (50.2% women 49.8% men, mean age 66.6 (13.5) years) who were admitted to sites since July 2019 who, absence contraindications, underwent thrombolytic therapy (TLT) within first 4.5 hours from onset stroke. Data collected as a continuous sample. According reperfusion protocol...
Systemic thrombolytic therapy (STLT) is an available method of treatment ischemic stroke (II) with proven efficacy. The efficacy and safety STLT in certain groups patients, particular diabetes mellitus type 2 (T2DM), are being discussed. To compare the STLC II patients T2DM, hyperglycemia normoglycemia.Eighty-six were examined, including 23 T2DM (7 newly diagnosed), 27 at onset 36 normoglycemia. Cardioembolic subtype was diagnosed 35%, atherothrombotic 29%, lacunar 7%. In other unknown....
To compare the efficacy and safety of systemic thrombolytic therapy (STLT) in patients with cardioembolic stroke (CE) versus other pathogenic subtypes ischemic (IS).The study included 147 patients, 62 women 85 men (mean age - 62.9±0.8 years) including 37 (25.2%) CE subtype IS (group 1) 110 pathogenetic 2). NIHSS Rankin scale were used to assess patient's neurological status.One hundred twenty-six discharged, 21 (14.3%) died. In 11 cause death was development symptomatic hemorrhagic...